CHE CHEMED CORP Insider Trading

CEO Kevin McNamara sells 2,000 shares at CHE; his sixth sale at this company in 36 months, continuing a pattern of net dispositions.

Kevin McNamara, Chemed's President and CEO, sold 2,000 shares, representing his sixth open-market sale at this company in the past 36 months. Over the same period, he has made no open-market purchases, painting a consistent picture of net selling. The stock currently trades well below its 52-week high, and the company remains profitable with solid revenue growth. McNamara's track record at Chemed has been mixed: at the 30-day horizon, three of his five prior sales saw the stock decline afterward (well-timed exits), while two saw gains (poorly-timed); at the 90-day horizon, only one of his five prior sales was followed by a decline, while four saw subsequent stock gains, meaning most prior exits were ultimately poorly timed. This ongoing sale comes at a time when the company's fundamentals remain intact, but the repeated selling pattern combined with mixed timing on prior exits suggests no clear conviction signal from the CEO level.

CEO McNamara sells 1,500 shares of CHE at $369.37; stock down 39.6% from 52-week high, prior sell-timing mixed at this ticker.

Kevin J. McNamara, president and CEO of Chemed, sold 1,500 shares at $369.37 on 2026-03-27, reducing his stake from 93,719 to 92,219 shares. The stock is currently trading at $374.09, down 39.6% from its 52-week high of $619.21 and down 8.8% over the past 30 days. At the same-ticker level, McNamara's prior four measurable sales at CHE show mixed timing results: two were well-timed (negative 90-day returns after the sale), while two were poorly timed (positive returns followed). His cross-ticker track record across 16 prior open-market sales shows a 53.33% well-timed rate, only modestly better than random timing. The modest sale size (-1.6% of holdings) and recent repeated selling activity (another sale just 15 days prior on 2026-03-12) against the backdrop of sustained stock underperformance merit monitoring for any shift in management's forward outlook.

CHE CEO Kevin McNamara sold 2,000 shares at $403.18 on 2026-03-12; stock down -35.1% from 52-week high.

Kevin McNamara, president and CEO of CHEMED CORP, sold 2,000 shares for $806,360.00, reducing his holdings from 95,719 to 93,719 shares. The sale occurred at $403.18, while the stock currently trades at $401.87, down 35.1% from its 52-week high of $619.21 and off 13.2% in the past 30 days. McNamara's cross-ticker track record shows 15 prior sells with a 53.33% well-timed rate at the 90-day mark, but his same-ticker history at CHE is mixed: 3 of 5 prior sales have resulted in positive 90-day returns (poorly timed sells), while 2 showed declines afterward (well-timed). The sale represents a modest 2.1% reduction in his CHE position while the company maintains solid fundamentals with $624.9M quarterly revenue, $64.2M net income, and a 22.86 P/E ratio. Investors should note the stock's recent sharp decline and assess whether this sale reflects operational concerns or routine portfolio management.

CEO McNamara sells 2,000 CHE shares at $437.55; stock down 28.8% from 52-week high.

Kevin J McNamara, president and CEO of Chemed Corp, sold 2,000 shares for $875,100.00 on 2025-11-24, reducing his holdings from 96,197 to 94,197 shares. The sale occurred at $437.55 per share, which is below the current price of $440.70 but represents a significant discount from the 52-week high of $619.21 (28.8% below peak). At this ticker, McNamara's prior four measurable same-ticker sales show a 75% well-timed rate (3 of 4 exhibited negative 90-day returns), suggesting a pattern of selling ahead of declines; however, the current sale's timing cannot yet be assessed. Chemed's fundamentals remain solid with revenue of $624.9M and net income of $64.2M in the latest quarter, supporting a P/E of 22.39, though annual revenue growth of 7.4% is moderate. The sale represents a small reduction (2.1% of pre-transaction holdings), typical of routine portfolio management for a CEO holding 94.2K shares.

CHE CEO McNamara sold 3,000 shares at $461.28; stock down 27.0% from 52-week high, held 96.2K post-trade.

Kevin J McNamara, president and CEO of Chemed Corp, sold 3,000 shares on 2025-09-26 at $461.28, reducing his holdings from 99.2K to 96.2K shares. The sale occurred as the stock trades 27.0% below its 52-week high of $619.21, and notably, his four prior sales at CHE all showed negative 90-day returns (ranging from -4.6% to -27.5%), suggesting his prior exit timing at this ticker has been well-executed relative to subsequent price declines. The company's fundamentals remain solid with a $6.6B market cap, 7.4% annual revenue growth, and P/E of 22.69, making this sale noteworthy for its timing pattern rather than any apparent distress signal. However, the stock has declined 1.3% over 30 days and 6.6% over 90 days, and McNamara retains substantial holdings (96.2K shares), indicating no broad liquidation despite the historically advantageous sale timing.

CHE CEO McNamara sells 2,000 shares at $428.55; stock down 30.9% from 52-week high, down 9.5% in 30d.

Kevin J McNamara, president and CEO of Chemed Corp, sold 2,000 shares on 2025-08-05 at $428.55, reducing holdings from 101,197 to 99,197 shares. The stock has declined significantly from its 52-week high of $619.21, trading at $428.08 (−30.9% from peak) and down −9.5% over the prior 30 days. His prior trades at CHE show a strong pattern: all 5 prior sales resulted in negative 90-day returns, with an average 90-day decline of −11.6% and a 100% well-timed rate. This current sale follows a similar backdrop—stock weakness and the insider's established history of selling into downward momentum at this ticker—though the small share count (2.0K shares, −2.0% of prior holdings) suggests a modest transaction relative to his position size and the company's $6.2B market cap.

Director George J Walsh III buys 200 CHE shares at $417.10; stock down -25.9% over 90 days

Director George J Walsh III purchased 200 shares of Chemed Corp at $417.10 on 2025-08-04, increasing his holdings from 3,323 to 3,523 shares. The purchase occurred against a backdrop of significant recent stock decline, with Chemed trading -25.9% over the prior 90 days and -9.5% over the past 30 days, well below its 52-week high of $619.21. The company maintains solid fundamentals with quarterly revenue of $618.8M, net income of $52.5M, and annual revenue growth of +7.4%, valuing the firm at $6.2B with a P/E of 21.48. The timing of this insider purchase during a period of substantial stock weakness merits attention regarding the director's assessment of valuation relative to the company's underlying operational performance.

EVP Westfall Nicholas Michael sells 10,012 (10.0K) CHE shares at $421.91; complete exit with strong prior sell-timing record at this ticker.

Westfall liquidated his entire position of 10,012 shares for $4,224,162.92 on 2025-08-04, leaving him with 0 shares post-transaction. His cross-ticker track record shows a 75.00% well-timed rate on prior sells, and at CHE specifically, 3 of 4 prior sells preceded declines. The current price of $428.08 is -30.9% from the 52-week high of $619.21, and the stock has fallen 25.9% over the past 90 days. CHE fundamentals remain solid with $618.8M quarterly revenue, $52.5M net income, and a P/E of 21.48, indicating the sale is not clearly explained by deteriorated operational performance. The complete exit, combined with a demonstrated pattern of well-timed sales at this ticker, merits investor attention to the broader stock momentum and any forward guidance changes.

EVP Lee Spencer sells 1,500 CHE shares at $577.99; 3 of 3 measurable prior CHE sells well-timed with negative 90d returns

EVP Lee Spencer sold 1,500 shares (9.3% of pre-transaction holdings) at $577.99 on 2025-05-16, reducing his position from 16,127 to 14,627 shares. His timing pattern at CHE is notable: his prior three measurable sales at this ticker (2024-11-22, 2024-08-08, and 2024-03-28) all showed negative 90-day returns of -2.8%, -5.2%, and -15.6% respectively, indicating the sales preceded declines. Cross-ticker, his broader track record shows 7 prior sells with a 60.00% well-timed rate at the 90-day mark. The current price of $578.02 sits 6.6% below the 52-week high, and the stock is up 5.0% over 90 days, suggesting Spencer may be executing ahead of potential pullback risk based on his demonstrated pattern at this ticker.

EVP Lee Spencer sells 1,500 CHE shares for $866.8K; stock down 8.1% from 52-week high

Lee Spencer S, executive vice president of Chemed Corp, sold 1,500 shares at $577.86 on 2025-05-07, reducing holdings from 17,627 to 16,127 shares (-8.5%). The sale occurred with CHE trading at -8.1% from its 52-week high of $619.21, placing the transaction in the lower end of the recent range. Spencer's prior trades at CHE show mixed timing outcomes: 3 of 4 measurable 90-day periods were well-timed (stock declined post-sale), but his most recent sale on 2025-03-03 was followed by +3.8% 30-day returns, suggesting the timing advantage does not hold consistently at this ticker. With the company trading at a P/E of 26.97 on $8.3B market cap and posting $646.9M quarterly revenue with +7.4% annual growth, the sale does not occur during an obvious fundamental deterioration.